Astellas

News

Zydus follows Lupin with Myrbetriq settlement deal

Zydus has joined Lupin in agreeing to settle patent litigation with Astellas on its generic of big-selling overactive bladder drug Myrbetriq.

News

Lupin settles Myrbetriq patent spat with Astellas for $90m

Lupin will be able to keep its generic of Astellas' overactive bladder therapy Myrbetriq on the US market, after reaching a settlement agreement.

Oncology

Astellas’ banner year and focused R&D strategy, with Adam Pe...

At JPM2026, Astellas' chief strategy officer Adam Pearson walked pharmaphorum through the company’s four-pillared R&D strategy.

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

News

EMA starts review of 'transformative' bladder cancer therapy

The EMA has started a review of a regimen based on Pfizer/Astellas' Padcev and MSD's Keytruda that is described as a game-changer for bladder cancer.

Oncology

Interview at ESMO 2025 with Tadaaki Taniguchi

ESMO25: On next-generation bispecifics, with Tadaaki Taniguc...

At ESMO 2025 in Berlin, pharmaphorum spoke with Tadaaki Taniguchi, Chief Research & Development Officer at Astellas.

Zydus follows Lupin with Myrbetriq settlement deal

Lupin settles Myrbetriq patent spat with Astellas for $90m

Astellas’ banner year and focused R&D strategy, with Adam Pe...

Padcev/Keytruda scores again in early bladder cancer

EMA starts review of 'transformative' bladder cancer therapy

ESMO25: On next-generation bispecifics, with Tadaaki Taniguc...

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Astellas

Editor's Picks